ACRS - Aclaris completes enrollment of mid-stage trial for atopic dermatitis

Aclaris Therapeutics ([[ACRS]] -4.7%) has completed the enrollment of a Phase 2a trial of ATI-1777, an investigational topical “soft” Janus kinase ("JAK") 1/3 inhibitor, in the treatment of moderate to severe atopic dermatitis (“AD”).The multicenter, randomized, double-blind, vehicle-controlled, parallel-group clinical trial is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ATI-1777 in patients with moderate to severe AD.The primary endpoint is the percentage change from baseline in the Eczema Area and Severity Index (“EASI”) score at week four after twice daily application of ATI-1777 or the vehicle.The company anticipates data from the trial in mid-2021.In January, Aclaris announced positive top-line results from a Phase 2a trial for ATI-450 in patients with moderate to severe rheumatoid arthritis (“RA”).

For further details see:

Aclaris completes enrollment of mid-stage trial for atopic dermatitis